

ZEPBOUND

PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit <https://www.bcbstx.com/provider/medicaid/pharmacy/rx-prior-auth>

PATIENT AND INSURANCE INFORMATION

Today's Date: _____

Patient Name (First):	Last:	M:	DOB (mm/dd/yy):
Patient Address:		City, State, Zip:	Patient Telephone:
BCBSTX ID Number:		Group Number:	

PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Phone #:	Secure Fax #:

PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient's Diagnosis-ICD code plus description:	
Medication Requested:	Strength:
Dosing Schedule:	Quantity per Month:
For all requests: 1. Is the patient currently treated with the requested agent? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes , when was treatment with the requested agent started? _____ 2. Does the patient have a diagnosis of moderate to severe obstructive sleep apnea (OSA) in the last 730 days? ... <input type="checkbox"/> Yes <input type="checkbox"/> No 3. Does the patient have an apnea-hypopnea index (AHI) of at least 15 events per hours on polysomnography (PSG) or home sleep apnea test (HSAT)? <input type="checkbox"/> Yes <input type="checkbox"/> No 4. Does the patient have a diagnosis of obesity in the last 730 days? <input type="checkbox"/> Yes <input type="checkbox"/> No 5. Will the patient use Zepbound in combination with a reduced calorie diet and increased physical activity? <input type="checkbox"/> Yes <input type="checkbox"/> No 6. Does the patient have a history of gastroparesis, medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2) in the last 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No 7. Will the patient have concurrent therapy with a GLP-1 RA containing agent? <input type="checkbox"/> Yes <input type="checkbox"/> No 8. Please list all other medications the patient will take in combination with the requested medication for the treatment of this diagnosis. _____ 9. Please list all reasons for selecting the requested agent, strength, dosing schedule, and quantity over alternatives (e.g., contraindications, allergies, history of adverse drug reactions to alternatives, lower dose has been tried, information supporting dose over FDA max). _____ 10. Please list all agents the patient has previously tried and failed for treatment of this diagnosis (Please specify if the patient has tried brand-name products, generic products, or over-the-counter products. Please specify start and end dates of drugs tried). _____ Date(s): _____ Date(s): _____ _____ Date(s): _____ Date(s): _____	

For renewal requests:

11. Has the patient lost or maintained a loss of at least 5% from their baseline weight? ☐ Yes ☐ No

Prescriber or Authorized Signature:

Date: _____

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

Please fax or mail this form to:

Prime Therapeutics LLC, Clinical Review Department
2900 Ames Crossing Road
Suite 200
Eagan, Minnesota 55121

TOLL FREE

Fax: 877.243.6930 Phone: 855.457.0407

CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.